JACC: Basic to Translational Science (Dec 2019)

A Novel Biological Strategy for Myocardial Protection by Intracoronary Delivery of Mitochondria: Safety and Efficacy

  • Borami Shin, MD,
  • Mossab Y. Saeed, MD,
  • Jesse J. Esch, MD,
  • Alvise Guariento, MD,
  • David Blitzer, MD,
  • Kamila Moskowitzova, MD,
  • Giovanna Ramirez-Barbieri, MD,
  • Arzoo Orfany, MD,
  • Jerusha K. Thedsanamoorthy, BA,
  • Douglas B. Cowan, PhD,
  • James A. Inkster, PhD,
  • Erin R. Snay, BRS,
  • Steven J. Staffa, MS,
  • Alan B. Packard, PhD,
  • David Zurakowski, PhD,
  • Pedro J. del Nido, MD,
  • James D. McCully, PhD

Journal volume & issue
Vol. 4, no. 8
pp. 871 – 888

Abstract

Read online

Summary: Mitochondrial dysfunction is the determinant insult of ischemia-reperfusion injury. Autologous mitochondrial transplantation involves supplying one’s healthy mitochondria to the ischemic region harboring damaged mitochondria. The authors used in vivo swine to show that mitochondrial transplantation in the heart by intracoronary delivery is safe, with specific distribution to the heart, and results in significant increase in coronary blood flow, which requires intact mitochondrial viability, adenosine triphosphate production, and, in part, the activation of vascular KIR channels. Intracoronary mitochondrial delivery after temporary regional ischemia significantly improved myocardial function, perfusion, and infarct size. The authors concluded that intracoronary delivery of mitochondria is safe and efficacious therapy for myocardial ischemia-reperfusion injury. Key Words: ischemia-reperfusion injury, mitochondria, mitochondrial transplantation, myocardial protection